Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 6.11
- Piotroski Score 5.00
- Grade Buy
- Symbol (IOVA)
- Company Iovance Biotherapeutics, Inc.
- Price $11.44
- Changes Percentage (-0.04%)
- Change -$0.01
- Day Low $11.03
- Day High $11.44
- Year High $18.33
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $23.00
- High Stock Price Target $40.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.81
- Trailing P/E Ratio -4.3
- Forward P/E Ratio -4.3
- P/E Growth -4.3
- Net Income $-444,037,000
Income Statement
Quarterly
Annual
Latest News of IOVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Can Giovanni Mpetshi Perricard Add More Guile To His Servebot Game?
Giovanni Mpetshi Perricard, a rising tennis star known for his powerful serves, is making waves in the ATP tour. Despite his dominance in serving, he faces challenges in longer rallies....
By Forbes | 5 days ago -
Tioga Cardiovascular announces first-in-human implantations of Luna TMVR system
Tioga Cardiovascular has successfully performed its first human trans-septal implantations using the Luna transcatheter mitral valve replacement system. The procedures, conducted in Paraguay and Georg...
By Yahoo! Finance | 1 week ago -
Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts?
The article discusses market volatility leading up to the 2024 election and suggests strategies for investors to navigate uncertainties. It highlights insights from experts regarding high-growth secto...
By Yahoo! Finance | 2 weeks ago
